

# A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

NCT07325526

---

Status	RECRUITING
Phase	Phase 2
Sponsor	Boehringer Ingelheim
Enrollment	30 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Male or female adults e18 to d75 years of age at the time of screening, and at least the legal age of consent in countries where it is  $\geq 18$  years
  - Patients meeting criteria for Child-Pugh category A without history of previous decompensation event
  - Compensated Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis diagnosed by 1 of the following:
    - Biopsy (collected during screening or d 5 years\* prior to screening) showing cirrhosis (fibrosis stage 4) with steatosis or steatohepatitis.
    - Biopsy (collected during screening or d 5 years\* prior to screening) showing cryptogenic cirrhosis.
- ... and 2 more (see full listing online)

### Exclusion (15)

- Patients with clinically significant portal hypertension defined by any of the following:
    - VCTE  $\geq 25$  kPa if the platelets are  $\geq 150,000/\mu\text{L}$
    - VCTE  $\geq 20$  kPa if platelets are  $< 150,000/\mu\text{L}$
  - History of esophageal or gastric varices (Grade e1) on endoscopy
  - ELF score  $\geq 11.3$
- ... and 10 more (see full listing online)

## Locations (21 total)

---

Southern California Research Center, Coronado, California, United States  
Velocity Clinical Research, San Diego, La Mesa, California, United States  
Catalina Research Institute, LLC, Montclair, California, United States  
... and 18 more locations